
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly is a well-established and successful drug firm, with a strong focus on neuroscience, cardiometabolic, cancer, and immunology drugs. The positive OUS Mounjaro adoption and incremental Foundayo launch suggest continued growth for the company, and the expected launch of retatrutide in 2027 adds potential for future success. Some key risks for investors to consider include potential pricing pressure, underperformance of certain pipeline products, and competition from other drug companies.
Bears say
Eli Lilly is facing potential negative press and stock decline due to reported cases of liver failure associated with their drug Verzenio. This could lead to decreased sales and a negative impact on the company's financials, potentially causing a decline in stock performance. Despite recent model changes and positive revenue and EPS guidance, there is still significant risk and uncertainty surrounding Eli Lilly's products, particularly in the oncology and immunology sectors.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares